Janssen Search
Search results
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Aug 10, 2023 United States Bispecific antibody targeting GPRC5D receptor showed an overall response rate of more than 70 percent with durable responses, including in patients previously treated with a bispecific antibody or CAR-T cell therapy HORSHAM, ...
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemother
Sep 06, 2023 United States MARIPOSA-2 is the first Phase 3 study to show statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the post-osimertinib setting MARIPOSA-2 is the second RYBREVANT ® Phase 3 study ...
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
Feb 13, 2023 United States Updated data from the Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer will be featured RARITAN, N.J., Feb. 13, 2023 -- ...
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Dec 10, 2022 United States Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a ...
Janssen Demonstrates Commitment to Transform the Treatment of Multiple Myeloma through Innovative Science and Industry-Leading Portfolio with Largest-Ever Presence at 20th International Myeloma Society Annual Meeting
Sep 27, 2023 United States Presentations to highlight latest data across biologic, bispecific and CAR-T therapies with added insights from Global Multiple Myeloma Call-to-Action RARITAN, N.J., September 27, 2023 — The Janssen Pharmaceutical Companies ...
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023
Sep 05, 2023 United States Key analyses examine long-term safety and efficacy of medicines for treatment-resistant depression and schizophrenia Titusville, New Jersey, September 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson ...
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
Jun 05, 2023 United States At 16-months median follow-up, CARVYKTI ® significantly improved progression-free survival compared to two standard treatment s [1] Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal ...